MedTrace Logo

Impact of Mupirocin Decolonization on the Nasal Microbiome

NCT02045329 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2018-10-17

No results posted yet for this study

Summary

The normal bacteria that inhabit the human nose, also known as the nasal microbiome, may serve as a host defense mechanism against colonization and infection by Staphylococcus aureus, including methicillin resistant S. aureus (MRSA). Mupirocin is a topical antibacterial agent that may be used to clear nasal colonization with S. aureus, and reduce risk of S. aureus infection. The impact of mupirocin on the normal nasal microbiome is not known. We hypothesize that the nasal microbiome is changed by mupirocin. Our study aims to define the nasal microbiome before and after decolonization therapy with mupirocin.

Conditions

  • Nasal Colonization With Staph Aureus

Sponsors & Collaborators

  • VA Eastern Colorado Health Care System

    lead FED

Principal Investigators

  • Mary T Bessesen, MD · Veterans Affairs Eastern Colorado Healthcare System

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-06-05
Completion
2015-06-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02045329 on ClinicalTrials.gov